Outpatient infusion centers advertise Aduhelm
Yes, but: Hardly any patient receives the drug, although infusion centers are eager to advertise it. Only 100 patients actually got Aduhelm so far, well below Biogen’s already temperate forecast, STAT reported.
Stay on top of the latest market trends and economic information with Axios Markets. Subscribe for free
What we see: Infusion centers that are not owned by hospitals attract potential patients from Aduhelm, some offering freebies.
IVX Health, who has just received $ 100 million from a private equity firm and operates 50 ambulatory care centers in affluent suburbs, says people who take Aduhelm can enjoy “big screen TVs, high-speed Wi-Fi, [and] free snacks. “
The chief neurologist of the memory processing centers boasted that “there is now real light and hope on the horizon” with Aduhelm, without acknowledging the side effects of the drug and lack of proof It works. The company did not respond to several phone calls and emails.
Infusion partners in Michigan said it began treating its first Aduhelm patients last month.
What they say : “We’re going to rely on the FDA and the processes it has to approve drugs, and then on the clinical expertise of the referring physician,” IVX Health CEO Doug Ghertner said in an interview after being interviewed. asked if the company had weighed the unproven evidence of Aduhelm. clinical benefits.
Like this article ? Get more Axios and subscribe for free to Axios Markets.